Targeted anti-vascular therapies for ovarian cancer: current evidence
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeted anti-vascular therapies for ovarian cancer: current evidence
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 108, Issue 2, Pages 250-258
Publisher
Springer Nature
Online
2013-02-06
DOI
10.1038/bjc.2012.541
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Using bevacizumab to treat metastatic cancer: UK consensus guidelines
- (2014) D Miles et al. BRITISH JOURNAL OF HOSPITAL MEDICINE
- The efficacy and safety of bevacizumab beyond first progression in patients treated with first-line mFOLFOX6 followed by second-line FOLFIRI in advanced colorectal cancer: a multicenter, single-arm, phase II trial (CCOG-0801)
- (2012) Goro Nakayama et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: Results from a large treatment observational cohort study
- (2012) Fairooz F. Kabbinavar et al. EUROPEAN JOURNAL OF CANCER
- OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- (2012) Carol Aghajanian et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer
- (2011) M. Zweifel et al. ANNALS OF ONCOLOGY
- Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO)
- (2011) A. Lortholary et al. ANNALS OF ONCOLOGY
- Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis
- (2011) J. Cortes et al. ANNALS OF ONCOLOGY
- Trastuzumab Treatment in Multiple Lines: Current Data and Future Directions
- (2011) M. Pegram et al. Clinical Breast Cancer
- Clinical Trials of Vascular Disrupting Agents in Advanced Non–Small-Cell Lung Cancer
- (2011) Mark J. McKeage Clinical Lung Cancer
- Safety of bevacizumab in metastatic breast cancer patients undergoing surgery
- (2011) Javier Cortés et al. EUROPEAN JOURNAL OF CANCER
- Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer
- (2011) David M. O'Malley et al. GYNECOLOGIC ONCOLOGY
- Efficacy of Trabectedin in Platinum-Sensitive-Relapsed Ovarian Cancer
- (2011) Nicoletta Colombo INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Big Costs for Little Gain in Ovarian Cancer
- (2011) Martee L. Hensley JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer
- (2011) Jonathan A. Ledermann et al. JOURNAL OF CLINICAL ONCOLOGY
- Venous Thromboembolic Events With Chemotherapy Plus Bevacizumab: A Pooled Analysis of Patients in Randomized Phase II and III Studies
- (2011) Herbert I. Hurwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer
- (2011) Beth Y. Karlan et al. JOURNAL OF CLINICAL ONCOLOGY
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
- (2011) Robert A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 3 Trial of Bevacizumab in Ovarian Cancer
- (2011) Timothy J. Perren et al. NEW ENGLAND JOURNAL OF MEDICINE
- From Chemotherapy to Targeted Therapy in Adjuvant Treatment for Stage III Colon Cancer
- (2011) Aimery de Gramont et al. SEMINARS IN ONCOLOGY
- A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study
- (2010) J. J. Biagi et al. ANNALS OF ONCOLOGY
- Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?
- (2010) D.L. Richardson et al. GYNECOLOGIC ONCOLOGY
- A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer
- (2010) Michael Friedlander et al. GYNECOLOGIC ONCOLOGY
- Activity of Sorafenib in Recurrent Ovarian Cancer and Primary Peritoneal Carcinomatosis: A Gynecologic Oncology Group Trial
- (2010) Daniela Matei et al. JOURNAL OF CLINICAL ONCOLOGY
- Disease Course Patterns After Discontinuation of Bevacizumab: Pooled Analysis of Randomized Phase III Trials
- (2010) David Miles et al. JOURNAL OF CLINICAL ONCOLOGY
- Bridging the Gap between Cytotoxic and Biologic Therapy with Metronomic Topotecan and Pazopanib in Ovarian Cancer
- (2010) William M. Merritt et al. MOLECULAR CANCER THERAPEUTICS
- Potent Preclinical Impact of Metronomic Low-Dose Oral Topotecan Combined with the Antiangiogenic Drug Pazopanib for the Treatment of Ovarian Cancer
- (2010) Kae Hashimoto et al. MOLECULAR CANCER THERAPEUTICS
- Paclitaxel chemotherapy and vascular toxicity as assessed by flow-mediated and nitrate-mediated vasodilatation
- (2010) M. Vassilakopoulou et al. VASCULAR PHARMACOLOGY
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
- (2009) John M.L. Ebos et al. CANCER CELL
- Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer
- (2009) J.D. Hurt et al. GYNECOLOGIC ONCOLOGY
- The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: A retrospective cohort study
- (2009) Gregory P. Sfakianos et al. GYNECOLOGIC ONCOLOGY
- When ‘never-events’ occur despite adherence to clinical guidelines: The case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes
- (2009) Linda R. Duska et al. GYNECOLOGIC ONCOLOGY
- Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma
- (2009) John P. Diaz et al. GYNECOLOGIC ONCOLOGY
- Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies
- (2009) James Cassidy et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer
- (2009) Ursula A. Matulonis et al. JOURNAL OF CLINICAL ONCOLOGY
- Intraperitoneal VEGF Inhibition Using Bevacizumab: A Potential Approach for the Symptomatic Treatment of Malignant Ascites?
- (2009) S. Kobold et al. ONCOLOGIST
- Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)
- (2008) Axel Grothey et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia
- (2007) Agustin A. Garcia et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started